In a landmark move for the nation’s healthcare landscape, the Union Budget 2026-27 has crossed the monumental Rs. 1 lakh crore allocation threshold, reaching a total of Rs. 1,05,599 crore.
This 4.75 per cent year-on-year increase marks what experts are calling a ‘watershed moment’, signalling India’s intent to transition from a volume-driven generics provider to a high-value, innovation-led global life-sciences powerhouse.
The centerpiece of this transformation is the ‘Biopharma Shakti’ initiative, a flagship program backed by a Rs. 10,000 crore outlay over the next five years. This strategic pivot aims to cultivate a robust domestic ecosystem for biologics, biosimilars, and advanced therapeutics. By establishing three new National Institutes of Pharmaceutical Education and Research (NIPERs) and upgrading seven existing ones, the government is making a clear bet on high-skilled research and talent development to drive the next decade of pharmaceutical growth.
The medical device sector is also witnessing a revolution, with the production-linked incentive (PLI) scheme successfully catalyzing complex manufacturing. For the first time, India is seeing the domestic production of high-value, import-dependent equipment such as MRI scanners, CT scanners, and linear accelerators. This shift is critical as the industry aims to reduce its heavy reliance on foreign medical technology, particularly in high-growth segments like cancer care and radiology.
To support this industrial expansion, the budget introduces a massive scale-up of clinical trial infrastructure, planning for 1,000 accredited sites across the country. By decentralizing these sites into Tier-2 and Tier-3 cities, the government hopes to accelerate drug development timelines and enhance regulatory credibility on the global stage. This is bolstered by the modernization of the CDSCO, which is being restructured to meet stringent international standards like those of the US FDA.
Patient affordability remains a core pillar of the new strategy, with the budget providing significant relief through customs duty exemptions on 17 critical cancer drugs and treatments for seven rare diseases. These measures are projected to save patients approximately Rs. 1,460 crore annually in cancer treatment costs alone. Furthermore, the AB PM-JAY health insurance scheme saw a sharp 24 per cent increase in funding to Rs. 9,406 crore, extending vital financial protection to more families and senior citizens.
Healthcare infrastructure is receiving a boost through the expansion of district hospital capacities and the creation of regional medical tourism hubs. These hubs will integrate traditional Ayush medicine with modern diagnostics, positioning India as a premier destination for global wellness tourism. The Ayush sector itself has seen its funding skyrocket to Rs. 3,993 crore, a testament to the government’s push for an integrated healthcare model.
Despite these strides, challenges remain, particularly the fact that public health spending still sits at 0.29 per cent of GDP, well below the national target of 2.5 per cent. Industry leaders have also noted the absence of restored R&D tax incentives and persistent delays in government reimbursements as potential hurdles to achieving the ambitious 2030 vision.
Looking ahead, the roadmap to 2030 envisions an Indian pharmaceutical market valued at 130 billion dollars and a medical device sector reaching up to 50 billion dollars. If the current momentum in regulatory reform and public-private partnerships is maintained, India is well on its way to fulfilling the ‘Viksit Bharat’ vision through excellence in the life-sciences.
|